Cited by 79Epigenetics and DNA MethylationTreatment of Major DepressionGenetic Associations and Epidemiology

Blood diagnostic biomarkers for major depressive disorder using multiplex DNA methylation profiles: discovery and validation

Open access
Numata, Shusuke, Ishii, Kazuo, Tajima, Atsushi, Iga, Jun-ichi, Kinoshita, Makoto, Watanabe, Shinya, Umehara, Hidehiro, Fuchikami, Manabu +7 more·2015·Epigenetics

Abstract

Aberrant DNA methylation in the blood of patients with major depressive disorder (MDD) has been reported in several previous studies. However, no comprehensive studies using medication-free subjects with MDD have been conducted. Furthermore, the majority of these previous studies has been limited to the analysis of the CpG sites in CpG islands (CGIs) in the gene promoter regions. The main aim of the present study is to identify DNA methylation markers that distinguish patients with MDD from non-psychiatric controls. Genome-wide DNA methylation profiling of peripheral leukocytes was conducted in two set of samples, a discovery set (20 medication-free patients with MDD and 19 controls) and a replication set (12 medication-free patients with MDD and 12 controls), using Infinium HumanMethylation450 BeadChips. Significant diagnostic differences in DNA methylation were observed at 363 CpG sites in the discovery set. All of these loci demonstrated lower DNA methylation in patients with MDD than in the controls, and most of them (85.7%) were located in the CGIs in the gene promoter regions. We were able to distinguish patients with MDD from the control subjects with high accuracy in the discriminant analysis using the top DNA methylation markers. We also validated these selected DNA methylation markers in the replication set. Our results indicate that multiplex DNA methylation markers may be useful for distinguishing patients with MDD from non-psychiatric controls.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/15592294.2014.1003743

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Among these 363 sites, several genes, including DGKH, GSK3B, and SGK1, have been identified as playing a role in major depressive disorder.

    “Among these 363 sites, several genes, including DGKH, GSK3B, and SGK1, have been identified as playing a role in MDD.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Numata, S., Ishii, K., Tajima, A., Iga, J.-I., Kinoshita, M., Watanabe, S., Umehara, H., Fuchikami, M., Okada, S., Boku, S., Hishimoto, A., Shimodera, S., Imoto, I., Morinobu, S., & Ohmori, T.
Affiliations
  • Tokushima University (JP)
  • Tokyo University of Agriculture and Technology (JP)
  • Kanazawa University (JP)
  • Hiroshima University (JP)
  • Kobe University (JP)
  • University of Kochi (JP)
Corresponding author
Numata, Shusuke
Venue
Epigenetics
Published
2015-01-14
Volume
10
Issue
2
Pages
135-141
ISSN
  • 1559-2294 (ISSN-L)
  • 1559-2308
OpenAlex
W1516580926
Cited by
79
References
45
Citations by year
2025: 4 · 2024: 3 · 2023: 3 · 2022: 8 · 2021: 13 · 2020: 4 · 2019: 9 · 2018: 10 · 2017: 14 · 2016: 8 · 2015: 3
FWCI
5.06
Type
journal article
Language
en
Open access
Locations
  • Epigenetics (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Tokushima
  • SENSHIN Medical Research Foundation
  • Japan Society for the Promotion of Science (15K09810, 26330325)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
major depressive disorder, DNA methylation, blood biomarkers, peripheral blood leukocytes, CpG islands, diagnostic biomarkers, medication-free patients, epigenetic biomarkers
MeSH terms
Glycogen Synthase Kinase 3 beta, Adult, Major Depressive Disorder, Female, Genetic Markers, Humans, Leukocytes, Male, Middle Aged, CpG Islands, DNA Methylation, Glycogen Synthase Kinase 3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review